Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage, Biogen's Zuranolone Meets Primary Endpoint in Phase 3 Trial

06/15/2021 | 05:00am EDT

By Matt Grossman

Sage Therapeutics Inc. and Biogen Inc. said Tuesday that their zuranolone drug's 50 mg dose met the primary endpoint in a Phase 3 trial.

The drug led to a statistically significant improvement in major-depressive symptoms compared with a placebo, Sage and Biogen said. Zuranolone is taken once daily and could potentially provide a fast-acting and sustainable treatment option for depression, the companies said.

The study included 543 patients aged 18 to 64. Their symptoms were measured using the Hamilton rating scale for depression.

The most common adverse events among people treated with zuranolone in the study were sleepiness, dizziness, headache and sedation, the companies said. About 3% of subjects stopped taking the drug because of adverse effects, the companies said.

Sage and Biogen said that they plan to discuss next steps toward regulatory approval with the Food and Drug Administration.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

06-15-21 0700ET

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 1.90% 338 Delayed Quote.38.04%
SAGE THERAPEUTICS, INC. -3.71% 41.76 Delayed Quote.-51.73%
All news about SAGE THERAPEUTICS, INC.
08/03SAGE THERAPEUTICS : Wedbush Adjusts Price Target for Sage Therapeutics to $80 Fr..
MT
08/03SAGE THERAPEUTICS : Narrows Q2 Loss as Revenue Grows
MT
08/03SAGE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
08/03SAGE THERAPEUTICS : Company announces REDWOOD and RAINFOREST Studies not expecte..
PU
08/03SAGE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financi..
AQ
08/03SAGE THERAPEUTICS : Announces Second Quarter 2021 Financial Results and Highligh..
BU
07/27SAGE THERAPEUTICS : Canaccord Genuity Adjusts Price Target on Sage Therapeutics ..
MT
07/23DGAP-NEWS : Il settore delle biotecnologie -2-
DJ
07/23PRESS RELEASE : Solid second quarter for the -2-
DJ
07/20SAGE THERAPEUTICS : to Report Second Quarter 2021 Financial Results on Tuesday, ..
BU
More news
Financials (USD)
Sales 2021 7,56 M - -
Net income 2021 -430 M - -
Net cash 2021 1 445 M - -
P/E ratio 2021 -5,71x
Yield 2021 -
Capitalization 2 442 M 2 442 M -
EV / Sales 2021 132x
EV / Sales 2022 9,75x
Nbr of Employees 298
Free-Float 87,1%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 41,76 $
Average target price 84,47 $
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
James Doherty Chief Research Officer
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.-51.73%2 442
GILEAD SCIENCES, INC.17.32%87 579
BIONTECH SE331.56%84 970
WUXI APPTEC CO., LTD.41.52%71 929
REGENERON PHARMACEUTICALS19.46%60 737
VERTEX PHARMACEUTICALS-15.36%51 899